[go: up one dir, main page]

ES2078440T3 - Compuestos farmaceuticos. - Google Patents

Compuestos farmaceuticos.

Info

Publication number
ES2078440T3
ES2078440T3 ES91303679T ES91303679T ES2078440T3 ES 2078440 T3 ES2078440 T3 ES 2078440T3 ES 91303679 T ES91303679 T ES 91303679T ES 91303679 T ES91303679 T ES 91303679T ES 2078440 T3 ES2078440 T3 ES 2078440T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compounds
methyl
benzodiacepine
theno
piperazinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91303679T
Other languages
English (en)
Spanish (es)
Inventor
Jiban Kumar Chakrabarti
Terrence Michael Hotten
David Edward Tupper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly Industries Ltd
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10674942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2078440(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Application granted granted Critical
Publication of ES2078440T3 publication Critical patent/ES2078440T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
ES91303679T 1990-04-25 1991-04-24 Compuestos farmaceuticos. Expired - Lifetime ES2078440T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909009229A GB9009229D0 (en) 1990-04-25 1990-04-25 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ES2078440T3 true ES2078440T3 (es) 1995-12-16

Family

ID=10674942

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91303679T Expired - Lifetime ES2078440T3 (es) 1990-04-25 1991-04-24 Compuestos farmaceuticos.

Country Status (33)

Country Link
EP (1) EP0454436B1 (fi)
JP (1) JP2527860B2 (fi)
KR (1) KR100195566B1 (fi)
CN (1) CN1028429C (fi)
AT (1) ATE127804T1 (fi)
AU (1) AU643267B2 (fi)
BG (1) BG61710B2 (fi)
CA (1) CA2041113C (fi)
CY (1) CY1900A (fi)
CZ (1) CZ279937B6 (fi)
DE (3) DE69112895D1 (fi)
DK (1) DK0454436T3 (fi)
ES (1) ES2078440T3 (fi)
FI (1) FI101379B1 (fi)
GB (1) GB9009229D0 (fi)
GE (1) GEP20032965B (fi)
GR (1) GR3017877T3 (fi)
HK (1) HK87596A (fi)
HU (2) HU212416B (fi)
IE (1) IE68401B1 (fi)
IL (2) IL97912A (fi)
LU (2) LU90009I2 (fi)
LV (1) LV10262B (fi)
MX (1) MX173791B (fi)
NL (2) NL970015I2 (fi)
NO (3) NO178766C (fi)
NZ (1) NZ237932A (fi)
PT (1) PT97446B (fi)
RU (1) RU2043992C1 (fi)
SI (1) SI9110739A (fi)
SK (1) SK279196B6 (fi)
YU (1) YU48049B (fi)
ZA (1) ZA913085B (fi)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817656A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Mental disorders
US5817657A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Psychoactive substance disorders
US5627178A (en) * 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5817655A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
ATE198891T1 (de) * 1992-05-29 2001-02-15 Lilly Co Eli Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems
US6034078A (en) * 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EP0733368A1 (en) * 1995-03-24 1996-09-25 Eli Lilly And Company Granule fomulation for olanzapine
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US6506746B2 (en) 1995-05-30 2003-01-14 Eli Lilly And Company Method for treating cognitive dysfunction
CN1131035C (zh) * 1995-05-30 2003-12-17 伊莱利利公司 治疗识别机能障碍的方法
PT828494E (pt) * 1995-05-30 2002-10-31 Lilly Co Eli Compostos farmaceuticos
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
JP2000502346A (ja) * 1995-12-21 2000-02-29 イーライ・リリー・アンド・カンパニー 皮膚炎の処置方法
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
NZ334346A (en) * 1996-09-23 2000-05-26 Lilly Co Eli Olanzapine dihydrate D comprising 2-methyl-4-(4-methyl-1-piperazinyl)-1OH-thieno[2,3-b][1,5]benzodiazepine and a formulation for use in treating central nervous system disorders
EP1016664B1 (en) 1997-09-02 2003-07-02 Mitsubishi Pharma Corporation Fused thiophene compounds and medicinal use thereof
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
KR100537713B1 (ko) * 1997-09-30 2005-12-20 일라이 릴리 앤드 캄파니 2-메틸-티에노-벤조디아제핀 제제
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
AU2001243475A1 (en) 2000-08-31 2002-03-13 Dr. Reddy's Laboratories Ltd. Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
RU2185383C1 (ru) * 2001-05-22 2002-07-20 Институт молекулярной генетики РАН ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
JP4530664B2 (ja) * 2001-12-24 2010-08-25 サン・ファーマシューティカル・インダストリーズ・リミテッド ２−メチル−４−（４−メチル−１−ピペラジニル）−１０Ｈ−チエノ［２，３−ｂ］［１，５］ベンゾジアゼピンの結晶形Ｉ、この結晶形Ｉの製造方法、及び医薬組成物
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
SI1513846T1 (sl) 2002-05-31 2011-11-30 Sandoz Ag Postopek za pripravo olanzapina form I
US20040063694A1 (en) * 2002-06-05 2004-04-01 Browder Monte R. Compound useful for the treatment of CNS disorders
PL199016B1 (pl) * 2002-06-20 2008-08-29 Adamed Sp Z Oo Sposób wytwarzania olanzapiny
SI21303A (sl) 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
DE10301923B3 (de) * 2003-01-17 2004-09-16 Krka Tovarna Zdravil, D.D. Verfahren und Zwischenprodukte zur Herstellung von Olanzapin
HU226410B1 (en) 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
EP1611139B1 (en) 2003-12-22 2008-06-04 Teva Pharmaceutical Industries Ltd. Methods of preparing olanzapine
WO2005070937A1 (en) * 2004-01-27 2005-08-04 Synthon B.V. A process for making olanzapine in a polymorph form i
EP1709053B1 (en) 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
AR048272A1 (es) * 2004-03-18 2006-04-12 Lek Pharmaceuticals Sintesis de 2 metil - 4- (4- metil -1- piperazinil) - 10 h- tieno ( 2,3-b) (1,5) benzodiazepina y sus sales, metodos para su preparacion, composiciones farmaceuticas que la contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mentales.
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
SI21850A (sl) * 2004-07-28 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Soli olanzapina in njihova pretvorba v prosto bazo olanzapina
CA2587710C (en) * 2004-11-16 2014-10-21 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
PL198589B1 (pl) 2004-11-22 2008-06-30 Adamed Sp Z Oo Sposób wytwarzania N-demetyloolanzapiny
JP4940152B2 (ja) 2005-01-05 2012-05-30 イーライ リリー アンド カンパニー パモ酸オランザピン二水和物
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
CN100383144C (zh) * 2006-09-11 2008-04-23 杭州盛美医药科技开发有限公司 一种奥氮平的中间体及其制备与应用
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2593407A1 (en) 2007-06-22 2008-12-22 Apotex Pharmachem Inc. Improved processes for the synthesis of olanzapine
CN101168544B (zh) * 2007-11-16 2010-11-17 西南合成制药股份有限公司 奥氮平的制备工艺
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
CN102532158A (zh) * 2010-12-17 2012-07-04 北大方正集团有限公司 一种合成奥氮平的方法
EP2486913A1 (en) 2011-02-14 2012-08-15 Labtec GmbH Rapidly disintegrating oral film formulation for Olanzapin
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
CN102225941B (zh) * 2011-06-01 2013-11-27 宁波人健医药化工有限公司 抗精神病药奥氮平的制备方法
WO2013066280A1 (en) * 2011-10-31 2013-05-10 Mahmut Bilgic Water soluble antipsychotic formulations
JP5934004B2 (ja) * 2012-03-22 2016-06-15 株式会社トクヤマ 結晶構造を有する４−アミノ−２−メチル−１０Ｈ−チエノ〔２，３−ｂ〕〔１，５〕ベンゾジアゼピン塩酸塩水和物及びその製造方法
US20150216206A1 (en) 2012-07-31 2015-08-06 Sanovel Hayvan Sagligi Urunleri Sanayi Ve Ticaret Anonim Sirketi Method for increasing meat and milk production
WO2014021803A1 (en) 2012-07-31 2014-02-06 Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret A.S. Use of olanzapine in animals
JP6042153B2 (ja) * 2012-09-26 2016-12-14 株式会社トクヤマ オランザピンの製造方法
KR101641902B1 (ko) 2015-06-24 2016-07-22 주식회사 네이처센스 농업회사법인 스트레스의 완화용 조성물
CN106265541A (zh) * 2016-08-31 2017-01-04 安徽省润生医药股份有限公司 一种注射用奥氮平及其制备方法
CN111004210A (zh) * 2019-10-23 2020-04-14 中山大学 化合物单晶及其制备方法
WO2025056094A1 (zh) * 2023-09-15 2025-03-20 广州帝奇医药技术有限公司 一种冻干制剂和注射液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
US3953430A (en) * 1975-02-24 1976-04-27 American Cyanamid Company Substituted benzodiazepin-10-ones and method of use
GB1533236A (en) * 1975-11-24 1978-11-22 Lilly Industries Ltd Thieno(1,5)benzodiazepine intermediates
GB1577743A (en) * 1977-05-17 1980-10-29 Lilly Industries Ltd Benzodiazepine derivatives

Also Published As

Publication number Publication date
DE69112895D1 (de) 1995-10-19
DE19675046I2 (de) 2001-05-23
KR910018387A (ko) 1991-11-30
LU90869I2 (fr) 2002-02-21
NL970015I2 (nl) 1997-09-01
ATE127804T1 (de) 1995-09-15
HU211575A9 (en) 1995-12-28
JPH0789965A (ja) 1995-04-04
FI911986A0 (fi) 1991-04-24
PT97446A (pt) 1992-01-31
ZA913085B (en) 1992-12-30
YU48049B (sh) 1996-10-18
DK0454436T3 (da) 1995-11-13
FI101379B (fi) 1998-06-15
DE69112895T4 (de) 2009-11-12
NO178766C (no) 1996-05-29
AU643267B2 (en) 1993-11-11
BG61710B2 (bg) 1998-03-31
NZ237932A (en) 1993-08-26
EP0454436B1 (en) 1995-09-13
IL97912A0 (en) 1992-06-21
IE911348A1 (en) 1991-11-06
NO178766B (no) 1996-02-19
HU212416B (en) 1996-06-28
CN1028429C (zh) 1995-05-17
KR100195566B1 (ko) 1999-06-15
MX173791B (es) 1994-03-25
NL300078I1 (nl) 2002-03-01
FI911986L (fi) 1991-10-26
HU911372D0 (en) 1991-10-28
NO1997005I1 (no) 1997-05-12
YU73991A (sh) 1994-01-20
NO911624L (no) 1991-10-28
LU90009I2 (fr) 1997-01-31
RU2043992C1 (ru) 1995-09-20
NL970015I1 (nl) 1997-06-02
JP2527860B2 (ja) 1996-08-28
NO2001028I1 (no) 2002-01-28
IE68401B1 (en) 1996-06-12
FI101379B1 (fi) 1998-06-15
LV10262A (lv) 1994-10-20
IL97912A (en) 1995-10-31
HK87596A (en) 1996-05-24
EP0454436A1 (en) 1991-10-30
CA2041113A1 (en) 1991-10-26
AU7518691A (en) 1991-11-07
SI9110739A (en) 1997-10-31
CN1056693A (zh) 1991-12-04
NO911624D0 (no) 1991-04-24
LV10262B (en) 1995-04-20
CZ279937B6 (cs) 1995-09-13
PT97446B (pt) 1997-07-31
GB9009229D0 (en) 1990-06-20
MX25502A (es) 1993-10-01
GEP20032965B (en) 2003-05-12
CS9101168A2 (en) 1991-12-17
CY1900A (en) 1991-04-24
CA2041113C (en) 1998-07-14
GR3017877T3 (en) 1996-01-31
IL112575A0 (en) 1995-05-26
SK279196B6 (sk) 1998-07-08
HUT60503A (en) 1992-09-28
DE69112895T2 (de) 1996-03-07

Similar Documents

Publication Publication Date Title
ES2078440T3 (es) Compuestos farmaceuticos.
TW372872B (en) Thieno[1,5]benzodiazepine use
ITMI930699A1 (it) Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
ES2079865T3 (es) Derivados del acido 4-hidroxi-butirico.
ATE74804T1 (de) Verringerung des durchmessers von rohrfoermigen koerpern.
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
ES2153842T3 (es) Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central.
ES2095984T3 (es) 2,3-dihidropirano(2,3-b)piridinas aminometil sustituidas, procedimiento para su preparacion y su uso en medicamentos.
MY105555A (en) Heterocyclicguanidines as 5ht 3 antagonists.
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
ES2190499T3 (es) Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer.
FI920553A0 (fi) Menetelmä lääkeaineina käyttökelpoisten kynureenihapon johdannaisten valmistamiseksi
MX9204896A (es) Tiazepinas substituidas como agentes del sistema nervioso central.
SE8802323L (sv) 8alfa-acylaminoergolin, dess framstaellning samt farmaceutiska kompositioner innehaallande detsamma
RU92015818A (ru) Способ для лечения энуреза
ATE90565T1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
PT84275A (en) Process for the preparation of tetracyclic quinazolinones

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 454436

Country of ref document: ES

SPCD Supplementary protection certificate rejected

Free format text: OLANZAPINA (ZYPREXA). MOTIVO: INCUMPLIMIENTO DE LOS ARTICULOS 7 Y 8. 1. B DE REGLAMENTO CEE 1768/92.

Spc suppl protection certif: C200100049

Filing date: 20011228

Effective date: 20040616